Kaixinren And Nikko Cordial Securities Sign Agreement
This article was originally published in PharmAsia News
Executive Summary
After receiving 100 million yuan in funding from Nikko Antfactory at the beginning of this year, Kaixinren chain drugstore has signed an agreement based on adjustable evaluation with Nikko Cordial Securities, which controls Nikko Antfactory. Nikko Antfactory will continue to pump $30 million yuan to $50 million yuan into Kaixinren within the next two years, with a goal of Kaixinren getting listed by 2010. Kaixinren has set out a 10-year strategy that includes opening 1,000 shops in three years, then gradually building up to 1,800 stores to become a world-class pharmaceutical corporation. It also aims to hit sales of 10 billion yuan within five to ten years. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.